for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Astellas Pharma Inc

4503.T

Latest Trade

1,897.00JPY

Change

27.50(+1.47%)

Volume

4,379,700

Today's Range

1,870.00

 - 

1,905.50

52 Week Range

1,375.00

 - 

1,987.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,869.50
Open
1,874.00
Volume
4,379,700
3M AVG Volume
101.81
Today's High
1,905.50
Today's Low
1,870.00
52 Week High
1,987.00
52 Week Low
1,375.00
Shares Out (MIL)
1,838.37
Market Cap (MIL)
3,528,087.00
Forward P/E
--
Dividend (Yield %)
2.06

Next Event

Dividend For 4503.T - 20.0000 JPY

Latest Developments

More

Health Canada Approves Astellas' drug For Acute Myeloid Leukemia

U.S. FDA Approves SNDA For Expanded Indication Of Mycamine For Treatment Of Invasive Candidiasis In Pediatric Patients Less Than 4 Months Of Age

Astellas Strengthens Immuno-Oncology Pipeline With Acquisition Of Xyphos Biosciences

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Astellas Pharma Inc

Astellas Pharma Inc. is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea, Taiwan and other markets through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive bladder agent Vesicare, Protopic ointment for atopic dermatitis, Harnal for prostatic and urethral smooth muscle, and antimycotic agent Funguard, among others. It also provides pharmaceutical products for gastritis, osteoporosis, hypertension, schizophrenia, rheumatoid arthritis, atopic dermatitis and other diseases. The Company also engages in the research and development of ophthalmology pharmaceuticals through its subsidiaries.

Contact Info

2-5-1, Nihombashihon-cho

+81.3.32443000

https://www.astellas.com/jp/

Executive Leadership

Yoshihiko Hatanaka

Chairman of the Board, Chairman of the Board of Directors, Representative Director

Kenji Yasukawa

President, Chief Executive Officer, Representative Director

Naoki Okamura

Vice President, Representative Director

Nobuaki Tanaka

Senior Executive Officer, Chief Director of Sales

Akihiko Iwai

Senior Executive Officer, Chief Director of Research

Key Stats

2.33 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

1.3K

2018

1.3K

2019

1.3K

2020(E)

1.3K
EPS (JPY)

2017

103.690

2018

81.110

2019

115.050

2020(E)

110.516
Price To Earnings (TTM)
16.19
Price To Sales (TTM)
2.74
Price To Book (MRQ)
2.68
Price To Cash Flow (TTM)
12.39
Total Debt To Equity (MRQ)
12.09
LT Debt To Equity (MRQ)
9.55
Return on Investment (TTM)
14.94
Return on Equity (TTM)
11.27

Latest News

Latest News

BRIEF-Astellas, Pfizer's Xtandi Demonstrates Significant Improvement In Overall Survival In Late-Stage Trial

* XTANDI® (ENZALUTAMIDE) DEMONSTRATES SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL IN PHASE 3 PROSPER TRIAL OF PATIENTS WITH NMCRPC Source text for Eikon:

BRIEF-Seattle Genetics, Astellas Says 73% Of Bladder Cancer Patients On Padcev Had Confirmed Tumor Response

* SEATTLE GENETICS AND ASTELLAS ANNOUNCE UPDATED RESULTS FROM PHASE 1B/2 TRIAL OF PADCEV™ (ENFORTUMAB VEDOTIN-EJFV) IN COMBINATION WITH IMMUNE THERAPY PEMBROLIZUMAB AS INVESTIGATIONAL FIRST-LINE TREATMENT FOR ADVANCED BLADDER CANCER

UPDATE 2-Astellas Pharma keeps profit forecast as prostate cancer drug sales rise

Japan's Astellas Pharma Inc reiterated its full-year operating profit forecast on Friday, as a jump in sales of its prostate cancer drug Xtandi countered overseas acquisition costs.

Astellas Pharma 9M operating profit rises 14% to 238 bln yen

Japan's Astellas Pharma Inc said operating profit rose 14% to 238 billion yen ($2.17 billion) in the nine months ending Dec. 31 and it maintained its full-year forecast.

Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million

Astellas Pharma Inc <4503.T> has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones and its second acquisition announced this month.

Astellas Pharma buys Xyphos Biosciences, deal worth up to $665 mln

Astellas Pharma Inc has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones and its second acquisition in as many months.

FDA grants accelerated approval for Astellas, Seattle Genetics' bladder cancer drug

(This December 18 story corrects third paragraph to remove reference to Padcev being the first FDA approved drug for advanced or metastatic urothelial cancer)

UPDATE 1-FDA approves expanded label for Pfizer, Astellas' prostate cancer therapy Xtandi

The U.S. Food and Drug Administration has approved Pfizer Inc and Astellas Pharma Inc's Xtandi to treat patients with a type of prostate cancer, the companies said on Monday.

FDA approves expanded label for Pfizer, Astellas' prostate cancer Xtandi

The U.S. Food and Drug Administration has approved Pfizer Inc and Astellas Pharma Inc's Xtandi to treat patients with a type of prostate cancer, the companies said on Monday.

Japan's Astellas to buy Audentes for $3 billion in high-priced gene therapy bet

Japan's Astellas Pharma Inc <4503.T> is buying U.S. drugmaker Audentes Therapeutics Inc <BOLD.O> for about $3 billion in cash, in a high-priced push to make genetic medicines a key area of growth.

CORRECTED-Japan's Astellas Pharma to buy Audentes Therapeutics for $2.7 bln

Japan's Astellas Pharma Inc said on Monday it had agreed to buy Audentes Therapeutics Inc for $2.7 billion in cash as it looks to bolster its position in the gene therapy market.

Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study

An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented...

CORRECTED-Seattle Genetics, Astellas drug shows rapid tumor shrinkage in advanced bladder cancer study

An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented...

Drugmakers Astellas, Amgen to pay $125 million in U.S. charity kickback probe

Two drugmakers will pay nearly $125 million (97 million pounds) to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their high-priced medications, the U.S. Justice Department...

Drugmakers Astellas, Amgen to pay $125 mln in U.S. charity kickback probe

Two drugmakers will pay nearly $125 million to settle claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their medications, the U.S. Justice Department said on Thursday.

Astellas Pharma gets U.S. nod for blood cancer treatment

The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan's Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation.

UPDATE 2-Astellas Pharma gets U.S. nod for blood cancer treatment

The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan's Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation.

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Drugmakers Pfizer Inc <PFE.N> and Astellas Pharma Inc <4503.T> said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.

BRIEF- Astellas Pharma signs exclusive licensing agreement with Aquinox Pharmaceuticals

* Says it signed an exclusive license agreement with Aquinox Pharmaceuticals, Inc for Japan and certain other countries in the Asia-Pacific region for Astellas to develop and commercialize rosiptor, Aquinox’s lead drug candidate, a first-in-class, once-daily oral treatment...

BRIEF-Aquinox And Astellas Announce Exclusive Licensing Agreement For Rosiptor In Asia-Pacific Region Including Japan

* AQUINOX AND ASTELLAS ANNOUNCE EXCLUSIVE LICENSING AGREEMENT FOR ROSIPTOR IN ASIA-PACIFIC REGION INCLUDING JAPAN

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up